Roche dis­con­tin­ues low dose in Hunt­ing­ton’s tri­al, will switch pa­tients to high dose

Roche is stop­ping pa­tients on the low dose of its ex­per­i­men­tal Hunt­ing­ton’s drug tomin­ersen, and will be tran­si­tion­ing them to the high dose fol­low­ing rec­om­men­da­tions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER